Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Aug 24, 2020 (6 years ago)

Strides Pharma Inc.Potassium Chloride Extended-Release Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Dissolution Specifications

Cause type: Dissolution failure

The tablet or capsule did not dissolve within specification. Dissolution controls how much drug the body absorbs; a failure can change the effective dose. All dissolution failure recalls.

What was recalled

Strides Pharma Inc.Potassium Chloride Extended-Release Tablets, USP 8mEq (600 mg) 100 Tablets Rx Only Manufactured by: Strides Pharma Science Limited Bengaluru -562106 India Distributed by: Strides Pharma Inc., East Brunswick NJ 08816 NDC 64380-860-06

Affected NDC 64380-0860-06

Compare with the code on your package — it is the most precise check available.

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Potassium Chloride
NDC 64380-0860
600 mg/1 Tablet, Extended Release
Oral
Strides Pharma Science Limited Rx
Recalling firm
Strides Inc.
NDC code
64380-860-06
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0001-2021 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other dissolution failure recalls from 2020

All dissolution failure recalls
Class II · Moderate risk

Vumerity (diroximel fumarate)

Failed dissolution specifications: out-of-specification test results observed during the buffer stage dissolution testing.

Terminated Dissolution failure Biogen MA Inc. NDC 64406-020-01 D-0148-2021